InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, will be represented at two investor events in March: the Emerging Growth Conference and the VirtualInvestorConferences.com—Life Sciences Investor Forum. InMed CEO Eric A. Adams will present at both conferences. His presentation at the Emerging Growth Conference, which is scheduled for March 9, 2023, will start at 12:30 p.m. ET and will include a corporate overview of the company as well as a question-and-answer session. Adams’ presentation for the Life Sciences Forum presentation is scheduled for March 9, 2023; it will start at 11 a.m. ET. That presentation will also include an overview of the company’s current position as well as time for questions and answers. In addition, members of the InMed management team will be available for virtual one-on-one meetings with institutional and individual investors from March 9–14.
To learn more about the Emerging Growth Conference, visit https://ibn.fm/0DURg
To learn more about the Life Sciences Investor Forum, visit https://ibn.fm/gq0ub
To view the full press release, visit https://ibn.fm/2MXzg
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
